Ceribell Reports Fourth Quarter and Full Year 2024 Financial Results
CeriBell, Inc. (CBLL)
Company Research
Source: GlobeNewswire
SUNNYVALE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 & Recent Highlights Reported total revenue of $18.5 million in the fourth quarter of 2024, a 41% increase compared to the same period in 2023Delivered total revenue of $65.4 million for the full year of 2024, a 45% increase over the prior yearEnded the year with 529 total active accounts Achieved gross margin of 88% in the fourth quarter of 2024 and 87% for the full year of 2024Submitted 510(k) application for pediatric Clarity™ algorithm to U.S. Food and Drug AdministrationAnnounced that Senior Vice President of Sales, Sean Manni, will be promoted to Chief Revenue OfficerAchieved new milestone in treating over 200,000 patients “2024 w
Show less
Read more
Impact Snapshot
Event Time:
CBLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CBLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CBLL alerts
High impacting CeriBell, Inc. news events
Weekly update
A roundup of the hottest topics
CBLL
News
- CeriBell (NASDAQ:CBLL) had its "buy" rating reaffirmed by analysts at BTIG Research.MarketBeat
- AI Diagnostics Hit Critical Mass as Hospitals Race to Cut CostsPR Newswire
- CeriBell (NASDAQ:CBLL) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring SolutionGlobeNewswire
- Ceribell Receives FDA 510(k) Clearance for Use of Clarity? Algorithm for NeonatesGlobeNewswire
CBLL
Earnings
- 11/4/25 - Beat
CBLL
Sec Filings
- 12/15/25 - Form 144
- 12/12/25 - Form 8-K
- 12/11/25 - Form 4
- CBLL's page on the SEC website